121 related articles for article (PubMed ID: 24025789)
1. Disruption of elastic lamellae in aorta and dysfunction of vaso-regulation by rofecoxib in rats.
Miyajima A; Okamoto M; Muto T; Hirota T
J Toxicol Sci; 2013; 38(5):719-29. PubMed ID: 24025789
[TBL] [Abstract][Full Text] [Related]
2. Disruption of elastic lamellae in the aorta by D-penicillamine and its effect on vaso-regulation in rats.
Muto T; Miyajima A; Bamba M; Hirota T
J Toxicol Sci; 2013; 38(5):707-17. PubMed ID: 24025788
[TBL] [Abstract][Full Text] [Related]
3. Mechanism for covalent binding of rofecoxib to elastin of rat aorta.
Oitate M; Hirota T; Takahashi M; Murai T; Miura S; Senoo A; Hosokawa T; Oonishi T; Ikeda T
J Pharmacol Exp Ther; 2007 Mar; 320(3):1195-203. PubMed ID: 17164475
[TBL] [Abstract][Full Text] [Related]
4. Covalent binding of radioactivity from [14C]rofecoxib, but not [14C]celecoxib or [14C]CS-706, to the arterial elastin of rats.
Oitate M; Hirota T; Koyama K; Inoue S; Kawai K; Ikeda T
Drug Metab Dispos; 2006 Aug; 34(8):1417-22. PubMed ID: 16679386
[TBL] [Abstract][Full Text] [Related]
5. Covalent binding of rofecoxib, but not other cyclooxygenase-2 inhibitors, to allysine aldehyde in elastin of human aorta.
Oitate M; Hirota T; Murai T; Miura S; Ikeda T
Drug Metab Dispos; 2007 Oct; 35(10):1846-52. PubMed ID: 17620346
[TBL] [Abstract][Full Text] [Related]
6. Maternal and postnatal vitamin D ingestion influences rat aortic structure, function and elastin content.
Norman P; Moss I; Sian M; Gosling M; Powell J
Cardiovasc Res; 2002 Aug; 55(2):369-74. PubMed ID: 12123776
[TBL] [Abstract][Full Text] [Related]
7. Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events.
Liu JY; Li N; Yang J; Li N; Qiu H; Ai D; Chiamvimonvat N; Zhu Y; Hammock BD
Proc Natl Acad Sci U S A; 2010 Sep; 107(39):17017-22. PubMed ID: 20837537
[TBL] [Abstract][Full Text] [Related]
8. Dysfunction of blood pressure regulation in hyperhomocyteinemia model in rats.
Miyajima A; Bamba M; Muto T; Hirota T
J Toxicol Sci; 2015 Apr; 40(2):211-21. PubMed ID: 25786525
[TBL] [Abstract][Full Text] [Related]
9. Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetic dependent.
Harirforoosh S; Aghazadeh-Habashi A; Jamali F
Clin Exp Pharmacol Physiol; 2006 Oct; 33(10):917-24. PubMed ID: 17002668
[TBL] [Abstract][Full Text] [Related]
10. [Assessment and truth -- how many cardio- and cerebrovascular events are in fact to be led back to taking rofecoxib].
Mühlbauer B; Timm J
Med Klin (Munich); 2006 Aug; 101(8):673-5; author reply 678-9. PubMed ID: 17051669
[No Abstract] [Full Text] [Related]
11. [How many harmed by rofecoxib in Germany?].
Scharnetzky E; Andersohn F; Schill W; Garbe E; Pigeot I
Med Klin (Munich); 2006 Aug; 101(8):675-6; author reply 678-9. PubMed ID: 17051670
[No Abstract] [Full Text] [Related]
12. Persistence of cardiovascular risk after rofecoxib discontinuation.
Ross JS; Madigan D; Konstam MA; Egilman DS; Krumholz HM
Arch Intern Med; 2010 Dec; 170(22):2035-6. PubMed ID: 21149763
[No Abstract] [Full Text] [Related]
13. Influence of D-penicillamine on the formation of elastin and its cross-links.
Ledvina M; Bartos F; Wimmerová J; Kosar A; Hodánová M
Physiol Bohemoslov; 1978; 27(6):521-9. PubMed ID: 152927
[TBL] [Abstract][Full Text] [Related]
14. Cerebrovascular events after discontinuation of rofecoxib treatment.
Andersohn F
Cardiovasc Drugs Ther; 2007 Apr; 21(2):77-9. PubMed ID: 17404824
[No Abstract] [Full Text] [Related]
15. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Valat JP; Deray G; Héloire F
Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
[TBL] [Abstract][Full Text] [Related]
16. Enhanced plasma concentration by selective deuteration of rofecoxib in rats.
Schneider F; Hillgenberg M; Koytchev R; Alken RG
Arzneimittelforschung; 2006; 56(4):295-300. PubMed ID: 16724516
[TBL] [Abstract][Full Text] [Related]
17. Potassium channel openers increase aortic elastic fiber formation and reverse the genetically determined elastin deficit in the BN rat.
Slove S; Lannoy M; Behmoaras J; Pezet M; Sloboda N; Lacolley P; Escoubet B; Buján J; Jacob MP
Hypertension; 2013 Oct; 62(4):794-801. PubMed ID: 23918751
[TBL] [Abstract][Full Text] [Related]
18. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
Kerr DJ; Dunn JA; Langman MJ; Smith JL; Midgley RS; Stanley A; Stokes JC; Julier P; Iveson C; Duvvuri R; McConkey CC;
N Engl J Med; 2007 Jul; 357(4):360-9. PubMed ID: 17652651
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension.
Reiff A; Lovell DJ; Adelsberg JV; Kiss MH; Goodman S; Zavaler MF; Chen PY; Bolognese JA; Cavanaugh P; Reicin AS; Giannini EH
J Rheumatol; 2006 May; 33(5):985-95. PubMed ID: 16583464
[TBL] [Abstract][Full Text] [Related]
20. Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban).
van der Hoorn JW; Jukema JW; Bekkers ME; Princen HM; Corda S; Emeis JJ; Steendijk P
Crit Care Med; 2008 Sep; 36(9):2576-82. PubMed ID: 18679128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
